Paclitaxel poliglumex - PG-TXL Company/University of Texas M D Anderson Cancer Center
Alternative Names: CHC 12103; CT-2103; Opaxio; PG - paclitaxel CTI BioPharma; PG-TXL; Poly(L-glutamic acid)-paclitaxel conjugate; Polyglutamate - Taxol; Polyglutamate-paclitaxel conjugate; Polyglutamic acid paclitaxel; PPX; Xyotax™Latest Information Update: 17 Nov 2021
At a glance
- Originator PG-TXL Company; University of Texas M. D. Anderson Cancer Center
- Developer Brown University; CTI BioPharma; Gynecologic Oncology Group; National Cancer Institute (USA); State University of New York
- Class Antineoplastics; Drug conjugates; Paclitaxels; Taxanes
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 05 Oct 2020 CTI BioPharma terminates the phase III STELLAR-3 trial for Non-small cell lung cancer (Late-stage disease, In adults, In the elderly, Combination therapy, Recurrent, First-line therapy) in USA (IV) (NCT00054210)
- 05 Oct 2020 CTI BioPharma terminates the phase III STELLAR-4 trial for Non-small cell lung cancer (Late-stage disease, In adults, In the elderly, Recurrent, First-line therapy) in USA (IV) (NCT00054197)
- 13 Mar 2019 Discontinued - Phase-I/II for Head and neck cancer (Combination therapy, Late-stage disease) in USA (IV)